Review characterizes systemic sclerosis as a disorder of maladaptive biological hyper-aging

A literature review published in Current Opinion in Rheumatology frames systemic sclerosis as an accelerated biological aging pathology, identifying cellular senescence and mitochondrial dysfunction as key drivers of progressive tissue fibrosis.

A systematic review published in Current Opinion in Rheumatology synthesized clinical and molecular evidence from the past 18 months, defining systemic sclerosis (SSc) as a state of 'hyper-aging' characterized by accelerated biological senescence.

The authors reported that epigenetic clock studies, including the DunedinPACE model, demonstrate accelerated biological aging in systemic sclerosis patients, particularly those presenting with interstitial lung disease and severe organ pathology.

The molecular cascade of SSc was shown to involve genomic instability, telomere shortening, and mitochondrial dysfunction, which lead to cytosolic DNA release and subsequent activation of the cGAS-STING pathway, driving chronic inflammation and tissue remodeling.

Reframing systemic sclerosis from a conventional autoimmune disease to an accelerated aging syndrome provides a concrete rationale for evaluating geroscience-focused assets in this indication.

The specific therapeutic targets highlighted—cellular senescence, mitochondrial stress, and downstream cGAS-STING signaling—suggest that interventions designed to extend healthy cellular lifespan could double as potent anti-fibrotic treatments.

The therapeutic alignment of cellular senescence with systemic sclerosis may encourage biotech companies with senolytic platforms to explore orphan-drug pathways in severe fibrotic conditions.

As clinical trials increasingly integrate epigenetic clocks like DunedinPACE as exploratory biomarkers, systemic sclerosis could serve as a valuable high-turnover model disease to validate the clinical efficacy of biological age-reversal candidates.